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Objective : Recent reports raised concerns on the durability of the Mitroflow aortic bioprosthesis, 
especially for the LXA-model without anticalcification treatment. This study reflects a single-center 
experience with the Mitroflow for aortic valve replacement (AVR)  
Method : From June 2003 to December 2014, 634 patients underwent AVR with the Mitroflow 
prosthesis. The study focused on 510 consecutive patients that received the LXA-prosthesis (2003-
2012), by addressing the end-points survival and prosthesis durability, with structural valve 
degeneration (SVD) defined by a mean transprosthetic  gradient > 30 mmHg at echocardiography 
and/or need for reoperation.  
Results : The mean patient age was 76±6 years, with 14% < 70 y and 23% > 80 y. Valve sizes 23 and 
25 were used in 70%, and 19 and 21 in only 18%, avoiding patient-prosthesis mismatch (PPM) in 91%. 
The mean follow-up time was 5.0±3.2 years, cumulating a total of 2152 patient-years (max 11.6 y). 
The 1-, 5-, and 8-year patient survival was 86±2%, 67±3%, and 47±3 % respectively. Freedom from 
SVD was 99±1% and 88±3 % at 5 and 8 years. Reoperation for SVD was performed in 3.3%, including 
redo-AVR (9) or TAVI (6) for cusp rupture (6) and stenotic calcified degeneration (9). Prosthetic 
explantation for endocarditis was done in 3 patients.  No specific patient- nor prosthesis-related 
factors significantly affected valve durability. SVD was not observed with the more recent Mitroflow 
model-DLA with phospholipid reduction therapy (used since May 2012), within a maximal follow-up 
time of 2.8 y. 
Conclusion : Despite lacking anticalcification treatment, the LXA-generation Mitroflow bioprosthesis 
offered a reliable aortic valve substitute in patients older than 70 years. The low occurrence of PPM, 
enhanced by its specific design and a consistent supra-annular implantation technique, might have 
improved the valve durability. Further results with the Mitroflow model-DLA have to be awaited. 
  
